Multiplikator forward rega marang pendapatan 10x (TXG)
Under the leadership of Serge Sakhsonov, 10x Genomics, Inc. (TXG) strives for leadership in single-cell analysis through patent protection. The organization's forward P/S visualizes market volatility, where 11.60 determines the latest valuation metric. Revenue is based on sales of consumables and Chromium instruments, although management is currently facing a slowdown in equipment sales rates.
Ringkesan rincian data analitis 10x (TXG)
- rega pasar lan target rega analis:
- rincian kapitalisasi pasar:
- rincian valuasi buku bisnis:
- informasi babagan utang lan solvabilitas:
Total Utang marang Modal 10x Genomics, Inc.|TXG - Rasio utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas 10x Genomics, Inc.|TXG - Gunggung kewajiban utang perusahaan|Utang marang nilai buku 10x|TXG - Gedhene kewajiban jangka dawa|Kewajiban jangka cendhak perusahaan 10x Genomics|Rasio cepet 10xgenomics.com
- rincian asil keuangan lan kelipatan valuasi:
TXG - Bathi resik taunan|Proyeksi bathi mangsa ngarep 10x Genomics, Inc.|TXG - Pangali rega marang bathi|Rega marang bathi mangsa ngarep 10x Genomics Corp|TXG - Rasio P/E diaturake wutah|Pangali EV/EBITDA 10x|TXG - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) 10x Genomics|TXG - Bathi saben saham sajrone patang kuartal pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan 10xgenomics.com|TXG - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep 10x Genomics, Inc.
- indikator volume dodolan lan pendapatan:
Analisis komprehensif perusahaan:10x Genomics (TXG)
The investment attractiveness of 10x Genomics, Inc. (TXG) depends on the company's ability to maintain its leadership in spatial biology amid intensifying competition and patent wars. This metric assesses the current share price relative to expected revenue, measuring market optimism regarding future sales. Sharp fluctuations in the forward price-to-sales ratio signal a revision of confidence in growth forecasts during periods of external shocks. Analyzing the amplitude of this chart helps determine the balance between speculative undervaluation and the risk of long-term capital depreciation.
Perusahaan pesaing
Rasio rega marang prakiraan pendapatan Tempus AI, Inc. TEM|Rasio kapitalisasi marang dodolan sing dikarepake Qiagen NV (QGEN)|IONS: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan RGEN (Repligen Inc.)|RNA: Multiplikator Forward P/S|CRSP - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan GeneDx|Kapitalisasi marang prakiraan pendapatan RARE (Ultragenyx Pharmaceutical Inc.)|Multiplikator Forward P/S BEAM|Multiplikator forward rega marang pendapatan Sarepta Corp SRPT|Twist Bioscience - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake intelliatx.com (NTLA)|STOK: Multiplikator forward rega marang pendapatan|BioLife Solutions Inc - Rasio rega marang pendapatan sing dikarepake|WVE (Wave Life Sciences Corp) - Multiplikator forward rega marang pendapatan|Kapitalisasi marang prakiraan pendapatan MAZE|SION (Sionna Therapeutics Inc) - Multiplikator Forward P/S|PRME - Prakiraan rega marang pendapatan|Multiplikator Forward P/S TSHA|uniQure NV - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan MeiraGTx PLC MGTX|RGNX: Kapitalisasi marang prakiraan pendapatan|Solid Biosciences Inc. - Multiplikator Forward P/S|OCGN - Multiplikator Forward P/S|PACB: Multiplikator Forward P/S|BNTC: Rasio rega marang pendapatan sing dikarepake|Multiplikator forward rega marang pendapatan DSGN|Kapitalisasi marang prakiraan pendapatan RCKT (Rocket Corp)|Multiplikator forward rega marang pendapatan FDMT (4D Molecular Therapeutics)|LXEO (lexeotx.com) - Rega forward marang dodolan|Multiplikator Forward P/S KRRO (Korro Bio)|Prakiraan rega marang pendapatan Editas Medicine Inc|Silence Therapeutics Inc. - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ProQR Therapeutics N.V.|codexis.com (CDXS) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan SGMO|Rasio rega marang prakiraan pendapatan Nautilus Biotechnology, Inc.|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Metagenomi Inc. MGX|Rasio rega marang prakiraan pendapatan Precision BioSciences, Inc. (DTIL)|Multiplikator forward rega marang pendapatan generationbio.com GBIO|Multiplikator Forward P/S BOLD (Boundless Bio, Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake Exicure Inc. (XCUR)|Celsion Corporation - Multiplikator Forward P/S|Phio Pharmaceuticals (PHIO) - Multiplikator forward rega marang pendapatan|mustangbio.com (MBIO) - Rasio rega marang prakiraan pendapatan|RNAZ - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan BNGO|APDN: Rega forward marang dodolan|Multiplikator Forward P/S BLUE|Rasio kapitalisasi marang dodolan sing dikarepake immunoprecise.com|Rasio rega marang prakiraan pendapatan Omega OMGA|OMIC: Kapitalisasi marang prakiraan pendapatan|Regulus Therapeutics - Multiplikator Forward P/S|syros.com (SYRS) - Multiplikator forward rega marang pendapatan|TBIO (Telesis Bio) - Multiplikator forward rega marang pendapatan|TCON - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan UBX
